The U.S. Food and Drug Administration indirectly refuted Pfizer’s recommendation that it’s all right for COVID-19 patients to take another round of Paxlovid if they experience a rebound after completing the first course.
The Omicron variant of the SARS-CoV-2 virus is intrinsically as severe as previous variants, unlike assumptions made in previous studies that it was more transmissible but less severe, a large study in the United States found.
Valneva said on May 4 the French drugmaker will conduct a trial about the use of the company’s COVID-19 vaccine candidate VLA2001 as a booster jab following a mRNA vaccination or natural infection.
COVID Americas cases up, North American cases up for 5th week – PAHO
Canada, Central America, Coronavirus Cases, Coronavirus Disease (COVID-19) Pandemic, COVID-19 cases, COVID-19 Infections, Hospitalizations, Hospitalized COVID-19 Patients, New Mexico, North America, Pan-American Health Organization (PAHO), Pandemics, Symptomatic COVID-19 Infections, Therapeutics, United StatesCOVID-19 cases in the Americas increased by 12.7 percent last week from the prior week, the Pan American Health Organization (PAHO) said on May 4, as infections continued to rise in Central and North America.
Moderna Inc. on May 4 forecast higher vaccine sales for the second half of 2022 than in the first six months of the year, as the company expects the virus that causes COVID-19 to follow a more seasonal pattern requiring booster shots in the fall.
COVID worsens asthma in children; booster after infection not as beneficial vs Omicron
Asthma, BNT162b2 (Pfizer and BioNTech), Children, COVID-19 booster shots, COVID-19 Studies, COVID-19 Vaccines, Doctors, Journal of Allergy and Clinical Immunology: In Practice, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Omicron (B.1.1.529) (South Africa), Polymerase Chain Reaction (PCR), R&DAsthma in children may worsen after an infection with the coronavirus, doctors warn. Additionally, among people who were previously infected with the coronavirus, a third dose of an mRNA vaccine from Pfizer/BioNTech or Moderna may not boost their protection against the Omicron variant of the virus, according to new data.
Pfizer Inc. maintained sales forecasts for the company’s pandemic products on May 3 after a series of hikes to revenue projections for its COVID-19 vaccine in 2021, in a sign that dizzying growth has slowed.
China’s commercial capital of Shanghai was dealt a blow on May 2 as authorities reported 58 new COVID-19 cases outside areas under strict lockdown, while Beijing pressed on with testing millions of people on a May Day holiday few were celebrating.
Moderna Inc.’s chief medical officer said on Sunday the company’s vaccine for children under 6 years old will be ready for review by a Food and Drug Administration panel when it meets in June.
COVID’s new Omicron sub-lineages can dodge immunity from past infection, study says
BNT162b2 (Pfizer and BioNTech), Clinical Trials, COVID-19 Antibodies, COVID-19 shots, COVID-19 Vaccines, Covid-19 Variants, Janssen COVID-19 Vaccine (J&J), Omicron (B.1.1.529) (South Africa), R&D, Scientists, South AfricaTwo new sublineages of the Omicron coronavirus variant can dodge antibodies from earlier infection well enough to trigger a new wave, but are far less able to thrive in the blood of people vaccinated against COVID-19, South African scientists found.